Attached files
| file | filename |
|---|---|
| EX-99.2 - EXHIBIT 99.2 - Cytosorbents Corp | v394028_ex99-2.htm |
| EX-99.1 - EXHIBIT 99.1 - Cytosorbents Corp | v394028_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): November 12, 2014
CYTOSORBENTS CORPORATION
(Exact name of registrant as specified in its charter)
| Nevada | 000-51038 | 98-0373793 |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
|
7 Deer Park Drive, Suite K, Monmouth Junction, New Jersey |
08852 |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (732) 329-8885
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 2.02 | Results of Operations and Financial Condition. |
On November 12, 2014, CytoSorbents Corporation (the “Company”) conducted a conference call during which members of
its senior management team discussed financial results for the third quarter and nine months ended September 30, 2014, a business
update, and certain other information. The transcript of the conference call is furnished herewith as Exhibit 99.1.
On November 12, 2014, the Company issued a press release announcing its financial results for the third quarter and nine months ended September 30, 2014. A copy of the press release is furnished herewith as Exhibit 99.2.*
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description |
| 99.1 | Transcript of the CytoSorbents Corporation Conference Call on November 12, 2014, 4:15 pm EST. |
| 99.2 | CytoSorbents Corporation Press Release, dated November 12, 2014. |
* The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: November 17, 2014 | CYTOSORBENTS CORPORATION | ||
| By: | /s/ Dr. Phillip P. Chan | ||
| Name: | Dr. Phillip P. Chan | ||
| Title: |
President and Chief Executive Officer |
||